ENDO 2026
Crinetics’ Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations
“At ENDO 2026, new data will be presented which increase the depth of clinical evidence supporting the long-term safety and efficacy of Palsonify for the treatment of acromegaly. In addition, updated data will be presented characterizing the potential of atumelnant to set an uncompromising bar for treating diseases of ACTH excess. I have often been frustrated by the lack of optimized treatments for these and many other difficult to manage endocrine conditions. At Crinetics, we are continuously working with many outstanding external investigator colleagues to redefine the possibilities.”
– Dr. Alan Krasner, M.D., Chief Endocrinologist, Crinetics
Presentation Schedule
Product Theaters
| Presentation Type | Title | Presenters | Date/Time | Location |
|---|---|---|---|---|
| Product Theater | Advancing Acromegaly Management: Bridging Clinical Evidence and the Patient Journey with PALSONIFY® (paltusotine) | Dr. Anthony Heaney and a patient living with acromegaly | June 15, 12:30 PM – 1:30 PM CST | ENDOExpo; Theater 1 |
PALSONIFY® (paltusotine) Presentations
| Presentation Type | Title | Presenters | Date/Time | Location |
|---|---|---|---|---|
| Poster Presentation | Long-Term Safety and Efficacy of Once-Daily Oral Paltusotine in Combination With Cabergoline for the Treatment of Patients With Acromegaly | Alessandra Casagrande, MD, Ph.D | June 14, 12:00 PM – 1:30 PM CT | McCormick Place West |
| Oral Presentation | Efficacy and Safety of Once-Daily Oral Paltusotine in Patients with Acromegaly: Up to 2 Years in the PATHFNDR-1 and PATHFNDR-2 Open-Label Extension Studies | Christian J. Strasburger, MD | June 14, 2:30 PM – 2:45 PM CT | Room W183BC |
| Poster Presentation | Real-World IGF-1 Control in Acromegaly: Insights from U.S. Claims and Laboratory Data | Raffaella Colzani, MD | June 15, 12:00 PM – 1:30 PM CT | McCormick Place West |
Atumelnant Presentations
| Presentation Type | Title | Presenters | Date/Time | Location |
|---|---|---|---|---|
| Rapid-Fire and Poster Presentations | Model-Informed Atumelnant Dose Selection for a Phase 3 Study in Adult Patients With Classic Congenital Adrenal Hyperplasia | Laura Curd, MS |
Rapid Fire: June 14, 1:45 PM – 1:50 PM CT Poster: June 15, 9:00 AM – 2:00 PM CT |
Rapid Fire: Room W184ABC Poster: ENDO Expo Hall, McCormick Place West |
| Oral Presentation | Once-Daily Atumelnant (CRN04894) Enables Lowering of Glucocorticoid Doses With Sustained Androgen Reduction in Adults With Congenital Adrenal Hyperplasia | Umasuthan Srirangalingam, FR, CP, Ph.D. | June 14, 2:10 PM – 2:25 PM CT | Room W184ABC |
| Oral Presentation | “Block and Replace” Atumelnant (CRN04894) and Physiologic Hydrocortisone Replacement Rapidly Controls Hypercortisolism in ACTH-Dependent Cushing Syndrome | Henrik Elenius, MD | June 14, 3:45 PM – 4:00 PM CT | Room W187 |
Presentation Download Library
Presentation materials will be available here following their live presentation at ENDO 2026.
PALSONIFY™ (paltusotine) Presentations:
Efficacy and Safety of Once-Daily Oral Paltusotine in Patients with Acromegaly: Up to 2 years in the PATHFNDR-1 and PATHFNDR-2 Open-Label Extension Studies
Long-Term Safety and Efficacy of Once-Daily Oral Paltusotine in Combination With Cabergoline for the Treatment of Patients With Acromegaly
Real-World IGF-1 Control in Acromegaly: Insights from U.S. Claims and Laboratory Data
Atumelnant Presentations
Once Daily Atumelnant (CRN04894) Enables Lowering of Glucocorticoid Doses With Sustained Androgen Reduction in Adults With Congenital Adrenal Hyperplasia
‘Block And Replace’ Atumelnant (CRN04894) And Physiologic Hydrocortisone Replacement Rapidly Controls Hypercortisolism In ACTH-dependent Cushing Syndrome
Model-Informed Atumelnant Dose Selection for a Phase 3 Study in Adult Patients With Classic Congenital Adrenal Hyperplasia
Exploring new frontiers with our science to expand patient reach
Our in-house R&D team of proven drug hunters develops transformative novel molecules with a focus on the endocrine system and G-protein coupled receptors. Our pipeline is purposefully created to deliver innovative therapies.
Please click CONTINUE below to learn more about a new treatment option. This website contains information about a prescription medicine.
